Journal
EXPERT OPINION ON DRUG SAFETY
Volume 9, Issue 3, Pages 383-396Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740331003592082
Keywords
adverse events; Asian patients; chemotherapy; culture; genetics; ixabepilone; metastatic breast cancer
Categories
Funding
- Bristol-Myers Squibb
Ask authors/readers for more resources
Areas covered in this review: Studies in Asian patients receiving other chemotherapeutics reported altered toxicity profiles for myelosuppression, neurotoxicity and gastrointestinal symptoms. Encouragingly, the limited clinical data in Asian patients receiving ixabepilone suggest that efficacy and toxicity in these women resemble those reported in the ixabepilone registrational trials. What the reader will gain: The reader will better understand how Asian genetics and culture may influence treatment outcomes and patient attitudes toward therapy and interaction with caregivers. Management of ixabepilone-related adverse events is also discussed with an emphasis on special considerations for Asian patients. Take home message: Awareness of possible altered drug response in Asian patients will aid clinicians in monitoring for toxicity, recognizing the need for dose modification and educating patients. Sensitivity to cultural aspects that are unique to Asians may improve adherence, reporting of adverse events and trust among Asian patients receiving ixabepilone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available